W. S. El-Deiry

This study shows that androgen receptor inhibitors enhance NK cell-mediated killing of prostate cancer cells and sensitivity to NKG2A checkpoint blockade by upregulating HLA-E expression.

This study shows that MRTX1133, a KRAS G12D inhibitor, synergizes with 5-FU or ONC212 to reduce tumor cell viability and pERK in CRC and pancreatic cancer cells, regardless of KRAS mutation status.

This study shows that combining lurbinectedin with irinotecan and 5-FU significantly enhances the killing of pancreatic cancer cells.

TRAIL agonists reduce radiation-induced lung injury and lethality in mice by inhibiting CCl22 and improving pneumonitis, alveolar-wall thickness, and oxygen desaturation.

This study shows that elraglusib enhances immune cell activation and synergizes with anti-PD-L1 in a murine colorectal cancer model, with clinical implications for combination immunotherapy.

The paper identifies CB002 analogues that restore p53 signaling and target an S-phase checkpoint in p53-mutated tumors, inducing apoptosis and reducing proliferation without harming normal cells.

This study identifies CHI3L1 as a key mediator of aging-related severity in COVID-19 by stimulating ACE2 and SPP expression, and shows it is a therapeutic target.

This study identifies Netrin G1 as a promoter of pancreatic ductal adenocarcinoma tumorigenesis by enhancing cancer-associated fibroblast-driven metabolic support and immunosuppression.